SEATTLE, Oct. 29 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that executives will present positive data and an overview of the company at two upcoming industry and/or investor conferences:
-- Nov. 12: Rodman & Renshaw 10th Annual Healthcare Conference at the New York Palace Hotel, 455 Madison Ave. in New York, N.Y. Michelle Burris, chief financial officer and senior vice president, is scheduled to present at 9:55 a.m. EST.
-- Nov. 18: Lazard Capital Markets 5th Annual Healthcare Conference at the St. Regis Hotel, 2 E. 55th St. at Fifth Avenue in New York, N.Y. Michelle Burris, chief financial officer and senior vice president, is scheduled to present at 11:25 a.m. EST.
Trubion is a biopharmaceutical company that is creating a pipeline of
novel protein therapeutic product candidates to treat autoimmune and
inflammatory diseases and cancer. The company's mission is to develop a
variety of first-in-class and best-in-class product candidates, customized
for optimal safety, efficacy, and convenience that it believes may offer
improved patient experiences. Trubion's current product candidates are
novel single-chain protein, or SMIP(TM), therapeutics, and are designed
using its custom drug assembly technology. Trubion's product pipeline
includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for
autoimmune and inflammatory diseases, developed under the company's Wyeth
collaboration. Trubion's product pipeline also includes Trubion's
proprietary product candidate, TRU-016, a novel CD37-targeted therapy for
the treatment of B-cell malignancies that is currently in Phase 1/2
clinical evaluation. In addition to Trubion's current clinical stage
|SOURCE Trubion Pharmaceuticals Inc.|
Copyright©2008 PR Newswire.
All rights reserved